Major Ingredients

Each film coated tablet contains Baricitinib INN 2.00 mg.

Major Functionality

Baricitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Limitation of Use: • Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressant’s such as azathioprine and cyclosporine. • For the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. • It is indicated for the treatment of adult patients with severe alopecia areata.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.